메뉴 건너뛰기




Volumn 65, Issue 3, 2008, Pages 364-376

Knowledge creation about ADRs - Turning the perspective from the rear mirror to the projector?

Author keywords

Adverse drug reactions; Knowledge; Pharmacoepidemiology; Phase II III clinical trials; Registrations files

Indexed keywords

ALATROFLOXACIN; AMOXICILLIN; AMOXICILLIN PLUS CLAVULANIC ACID; AMPICILLIN; AZTREONAM; BENSERAZIDE PLUS LEVODOPA; CARBIDOPA PLUS LEVODOPA; CEFACLOR; CEFOXITIN; CEFPODOXIME; CEFPODOXIME PROXETIL; CEFTAZIDIME; CEFTRIAXONE; CILASTATIN PLUS IMIPENEM; CIPROFLOXACIN; CLARITHROMYCIN; CLINDAMYCIN; DOXYCYCLINE; ERYTHROMYCIN; FLUCLOXACILLIN; GENTAMICIN; METRONIDAZOLE; NORFLOXACIN; OFLOXACIN; PIPERACILLIN PLUS TAZOBACTAM; RITUXIMAB; TOLCAPONE; TROVAFLOXACIN; UNINDEXED DRUG; VANCOMYCIN;

EID: 39849088723     PISSN: 03065251     EISSN: 13652125     Source Type: Journal    
DOI: 10.1111/j.1365-2125.2007.03019.x     Document Type: Article
Times cited : (16)

References (19)
  • 2
    • 0032167396 scopus 로고    scopus 로고
    • Withdrawal of Posicor from market. Circulation. 98:
    • SoRelle R. Withdrawal of Posicor from market. Circulation. 1998 98 : 831 2.
    • (1998) , pp. 831-2
    • Sorelle, R.1
  • 3
    • 39849111401 scopus 로고    scopus 로고
    • EMEA. Sertindole. (last accessed: 13 October 2006)
    • EMEA. Sertindole http://www.emea.eu.int/pdfs/human/referral/Sertindole/ 285202en.pdf (last accessed: 13 October 2006)
  • 4
    • 9944234075 scopus 로고    scopus 로고
    • Vioxx, the implosion of Merck, and the after shocks at the FDA
    • Horton R. Vioxx, the implosion of Merck, and the after shocks at the FDA. Lancet 2004 364 : 1995 6.
    • (2004) Lancet , vol.364 , pp. 1995-6
    • Horton, R.1
  • 5
    • 32844475507 scopus 로고    scopus 로고
    • Case reports of suspected adverse drug reactions - Systematic literature survey of follow-up
    • Loke Y, Price D, Derry S, Aronson JK. Case reports of suspected adverse drug reactions - systematic literature survey of follow-up. BMJ 2006 332 : 335 9.
    • (2006) BMJ , vol.332 , pp. 335-9
    • Loke, Y.1    Price, D.2    Derry, S.3    Aronson, J.K.4
  • 6
    • 33845936109 scopus 로고    scopus 로고
    • Anecdotes that provide definitive evidence
    • Aronson JK, Hauben M. Anecdotes that provide definitive evidence. BMJ 2006 333 : 1267 9.
    • (2006) BMJ , vol.333 , pp. 1267-9
    • Aronson, J.K.1    Hauben, M.2
  • 7
    • 39849087933 scopus 로고    scopus 로고
    • CHMP's Assessment Report on the Suspension of Trovan. EMEA/H/C/158/00/0/0/ (internal document).
    • CHMP's Assessment Report on the Suspension of Trovan. EMEA/H/C/158/00/0/0/ (internal document).
  • 8
    • 39849109289 scopus 로고    scopus 로고
    • CHMP's Assessment Report on Suspension of Alatrofloxacin. EMEA/H/C/160/00/0/0/ (internal document).
    • CHMP's Assessment Report on Suspension of Alatrofloxacin. EMEA/H/C/160/00/0/0/ (internal document).
  • 9
    • 39849099895 scopus 로고    scopus 로고
    • CHMP's Assessment Report on the Suspension of Tolcapon. EU/1/97/044/001-006 (internal document).
    • CHMP's Assessment Report on the Suspension of Tolcapon. EU/1/97/044/001-006 (internal document).
  • 10
    • 39849103203 scopus 로고    scopus 로고
    • CHMP's Assessment Report on the Evaluation of MabThera. EMEA/40532/98 (internal document).
    • CHMP's Assessment Report on the Evaluation of MabThera. EMEA/40532/98 (internal document).
  • 13
    • 39849085141 scopus 로고    scopus 로고
    • Rapporteurs' Assessment Report of the Dossier of Trovan. EMEA/H/C/158/159/160/161 (internal document).
    • Rapporteurs' Assessment Report of the Dossier of Trovan. EMEA/H/C/158/159/160/161 (internal document).
  • 14
    • 39849092634 scopus 로고    scopus 로고
    • Rapporteurs' Assessment Report of the Dossier of Tasmar. EMEA/H/C/131/00-01/0/0 (internal document).
    • Rapporteurs' Assessment Report of the Dossier of Tasmar. EMEA/H/C/131/00-01/0/0 (internal document).
  • 15
    • 39849085897 scopus 로고    scopus 로고
    • Rapporteurs' Assessment Report of the Dossier of MabThera. EMEA/H/C/165/01/01 (internal document).
    • Rapporteurs' Assessment Report of the Dossier of MabThera. EMEA/H/C/165/01/01 (internal document).
  • 16
    • 39849092475 scopus 로고    scopus 로고
    • EMEA. EPARs for authorised medicinal products for human use. (last accessed: 13 October 2006)
    • EMEA. EPARs for authorised medicinal products for human use. http://www.emea.europa.eu/humandocs/Humans/EPAR/tasmar/tasmar.htm (last accessed: 13 October 2006)
  • 18
    • 34547845289 scopus 로고    scopus 로고
    • Creating knowledge about adverse drug reactions: A critical analysis of the Danish reporting system from 1968 to 2005
    • Jun 11; [Epub ahead of print].
    • Aagaard L, Soendergaard B, Andersen E, Kampmann JP, Hansen EH. Creating knowledge about adverse drug reactions: a critical analysis of the Danish reporting system from 1968 to 2005. Soc Sci Med 2007 Jun 11; [Epub ahead of print].
    • (2007) Soc Sci Med
    • Aagaard, L.1    Soendergaard, B.2    Andersen, E.3    Kampmann, J.P.4    Hansen, E.H.5
  • 19
    • 0026664334 scopus 로고
    • Technology assessment in a user perspective - Experiences with drug technology
    • Hansen EH. Technology assessment in a user perspective - experiences with drug technology. Int J Technol Assess Health Care 1992 8 : 150 65.
    • (1992) Int J Technol Assess Health Care , vol.8 , pp. 150-65
    • Hansen, E.H.1


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.